Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gintant

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
American Heart Journal|June 16, 2019
Assessing cardiac safety in oncology drug developmentJonathan H Seltzer, Gary Gintant, Laleh Amiri-Kordestani, et al.
Journal of Clinical Pharmacology|April 20, 2018
Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and PharmacyJ Rick Turner, Ignacio Rodriguez, Emily Mantovani, et al.
Lab on a Chip|January 20, 2021
Cardiovascular microphysiological systems (CVMPS) for safety studies - a pharma perspectiveAmy Pointon, Jonathan Maher, Myrtle Davis, et al.
Journal of Pharmacological and Toxicological Methods|April 19, 2012
How do the top 12 pharmaceutical companies operate safety pharmacology?Lorna Ewart, David J Gallacher, Gary Gintant, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 11, 2022
The Challenges of Predicting Drug-Induced QTc Prolongation in HumansJean-Pierre Valentin, Peter Hoffmann, Catherine Ortemann-Renon, et al.
American Heart Journal|March 30, 2013
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research ConsortiumPhilip Sager, Jeffrey Heilbraun, J Rick Turner, et al.
Regulatory Toxicology and Pharmacology : RTP|October 10, 2012
Integrated and translational nonclinical in vivo cardiovascular risk assessment: gaps and opportunitiesBrian R Berridge, Peter Hoffmann, James R Turk, et al.
Frontiers in Pharmacology|August 27, 2019
Considerations for an <i>In Vitro</i>, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing PlatformsBrian D Guth, Michael Engwall, Sandy Eldridge, et al.
American Heart Journal|June 15, 2016
The Cardiac Safety Research Consortium enters its second decade: An invitation to participateJ Rick Turner, Peter R Kowey, Ignacio Rodriguez, et al.
Frontiers in Pharmacology|September 27, 2019
Considerations for an <i>In Vitro</i>, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-CardiomyocytesAlexandre J S Ribeiro, Brian D Guth, Michael Engwall, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
American Heart Journal|June 16, 2019
Assessing cardiac safety in oncology drug developmentJonathan H Seltzer, Gary Gintant, Laleh Amiri-Kordestani, et al.
Journal of Clinical Pharmacology|April 20, 2018
Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and PharmacyJ Rick Turner, Ignacio Rodriguez, Emily Mantovani, et al.
Lab on a Chip|January 20, 2021
Cardiovascular microphysiological systems (CVMPS) for safety studies - a pharma perspectiveAmy Pointon, Jonathan Maher, Myrtle Davis, et al.
Journal of Pharmacological and Toxicological Methods|April 19, 2012
How do the top 12 pharmaceutical companies operate safety pharmacology?Lorna Ewart, David J Gallacher, Gary Gintant, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 11, 2022
The Challenges of Predicting Drug-Induced QTc Prolongation in HumansJean-Pierre Valentin, Peter Hoffmann, Catherine Ortemann-Renon, et al.
American Heart Journal|March 30, 2013
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research ConsortiumPhilip Sager, Jeffrey Heilbraun, J Rick Turner, et al.
Regulatory Toxicology and Pharmacology : RTP|October 10, 2012
Integrated and translational nonclinical in vivo cardiovascular risk assessment: gaps and opportunitiesBrian R Berridge, Peter Hoffmann, James R Turk, et al.
Frontiers in Pharmacology|August 27, 2019
Considerations for an <i>In Vitro</i>, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing PlatformsBrian D Guth, Michael Engwall, Sandy Eldridge, et al.
American Heart Journal|June 15, 2016
The Cardiac Safety Research Consortium enters its second decade: An invitation to participateJ Rick Turner, Peter R Kowey, Ignacio Rodriguez, et al.
Frontiers in Pharmacology|September 27, 2019
Considerations for an <i>In Vitro</i>, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-CardiomyocytesAlexandre J S Ribeiro, Brian D Guth, Michael Engwall, et al.
Pageof 4